

Venus to sell Meropenem in Australia, ties up with Lupin

PRESS TRUST OF INDIA

Chandigarh

PHARMA major Venus Remedies on Monday said it has received marketing authorisation for its antibiotic drug Meropenem from Australian regulator TGA and has tied up with Lupin to sell the drug there.

The Panchkula-based company said it plans to roll out the drug by the third quarter of 2014 and is eyeing sizeable share in Australia's \$15 million Meropenem market in the first year of launch.

"The marketing authorisation from TGA (Therapeutic Goods Administration) has once again proved the company's capabilities in developing world-class products that meet the most stringent regulatory requirements," said Venus chairman and MD Pawan Chaudhary in a statement.

He said the company has tied-up with Lupin to market this drug in Australia.

Meropenem is an off-patent antibacterial agent of carbapenem class of antibiotics that caters to dis-

eases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children.

"Venus Remedies is already selling Meropenem in lucrative markets like Europe, New Zealand and Saudi Arabia. It is also in the process of extending sales operations to other regulated markets like Canada and Switzerland", Chaudhary said.

With marketing approvals from more than 35 countries, Venus Remedies is poised to capture a significant share in the \$1.3 billion global Meropenem

New market

■ The Panchkula-based company said it plans to roll out the drug by the third quarter of 2014

■ It is eyeing sizeable share in Australia's \$15 million Meropenem market in the first year of launch

■ The company has tied-up with Lupin to market this drug in Australia



market, he said.

Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.

Company has two manufacturing facilities located in India and Germany. Company manufactures Oncological and Cefalosporine Injectable products.

Its manufacturing facility located in India has received ISO 9001, ISO, 14001 and OHSAS 18001 for quality management. Its Germany facility follows EU-GMP norms.

Company